Published in Drugs R D on March 01, 2015
Catatonic Symptoms Appearing before Autonomic Symptoms Help Distinguish Neuroleptic Malignant Syndrome from Malignant Catatonia. Intern Med (2016) 0.75
A Case Report of Catatonia and Neuroleptic Malignant Syndrome With Multiple Treatment Modalities: Short Communication and Literature Review. Medicine (Baltimore) (2015) 0.75
Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists. Ital J Pediatr (2016) 0.75
The "Insight Paradox" in Schizophrenia: Magnitude, Moderators and Mediators of the Association Between Insight and Depression. Schizophr Bull (2016) 0.75
Patients reasons for obtaining psychotropic medications without a prescription at retail pharmacies in Central Saudi Arabia. Neurosciences (Riyadh) (2016) 0.75
Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatr Dis Treat (2017) 0.75
Paliperidone Inducing Concomitantly Syndrome of Inappropriate Antidiuretic Hormone, Neuroleptic Malignant Syndrome, and Rhabdomyolysis. Case Rep Crit Care (2016) 0.75
Risks and Benefits of Rapid Clozapine Titration. Ment Illn (2016) 0.75
Drug-induced oral lichenoid reactions: a real clinical entity? A systematic review. Eur J Clin Pharmacol (2017) 0.75
Neuroleptic malignant syndrome following catatonia: Vigilance is the price of antipsychotic prescription. SAGE Open Med Case Rep (2017) 0.75
Artesunate prevents rats from the clozapine-induced hepatic steatosis and elevation in plasma triglycerides. Neuropsychiatr Dis Treat (2017) 0.75
Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association. BJPsych Bull (2017) 0.75
Neuroleptic malignant syndrome. Am J Psychiatry (1985) 3.70
Neuroleptic malignant syndrome. Am J Psychiatry (2007) 3.64
Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry (2004) 3.12
Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry (1999) 2.83
Neuroleptic malignant syndrome. Med Clin North Am (1993) 2.56
Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf (2010) 2.20
Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool. Ann Pharmacother (2011) 2.09
Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand (2009) 2.07
Mortality from neuroleptic malignant syndrome. J Clin Psychiatry (1989) 1.99
An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry (2011) 1.80
The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry (2003) 1.73
Neuroleptic malignant syndrome associated with olanzapine. Ann Pharmacother (1998) 1.64
Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol (1995) 1.62
Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs (2006) 1.54
Effects of newer antipsychotics on extrapyramidal function. CNS Drugs (2002) 1.50
Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry (1986) 1.47
The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand (1986) 1.45
Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. World J Biol Psychiatry (2007) 1.43
An unrecognised case of withdrawal neuroleptic malignant syndrome: a case report. Med Sci Law (2009) 1.40
Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother (1999) 1.26
Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs (2009) 1.17
Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis (1994) 1.14
Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther (1997) 1.13
Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry (1998) 1.12
The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov (2009) 1.12
Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome. J Clin Psychiatry (2004) 1.03
A rating scale for neuroleptic malignant syndrome. Psychiatry Res (2005) 1.03
Possible neuroleptic malignant syndrome during paliperidone administration: a case report. J Clin Psychopharmacol (2010) 1.02
The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol (2001) 1.02
Ziprasidone- and lithium-induced neuroleptic malignant syndrome. Ann Pharmacother (2005) 1.01
Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry (2012) 1.01
The pharmacokinetics of paliperidone versus risperidone. Psychosomatics (2010) 0.99
Neuroleptic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride. Gen Hosp Psychiatry (2008) 0.97
Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther (2004) 0.96
Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine. Schizophr Res (2008) 0.95
Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet (1993) 0.95
Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Curr Drug Saf (2009) 0.95
Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol (2004) 0.95
Neuroleptic malignant syndrome after neuroleptic discontinuation. Prog Neuropsychopharmacol Biol Psychiatry (1995) 0.94
Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatr Scand (2005) 0.93
Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry (2012) 0.92
Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry (1992) 0.92
Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. J Emerg Med (2000) 0.91
Neuroleptic malignant syndrome following combination of sertraline and paroxetine: a case report. Gen Hosp Psychiatry (2013) 0.91
Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis (1986) 0.90
Neuropletic malignant syndrome and olanzapine. J Clin Psychopharmacol (2000) 0.90
Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf (2003) 0.89
Quetiapine and citalopram: aetiological significances in serotonin syndrome. N Z Med J (2006) 0.89
Amisulpride-induced neuroleptic malignant syndrome. J Neuropsychiatry Clin Neurosci (2007) 0.87
Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol (1999) 0.86
Atypical neuroleptic malignant syndrome associated with clozapine treatment. Neuropsychobiology (1997) 0.86
Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand (2013) 0.86
Are neuroleptic malignant syndrome and serotonin syndrome the same syndrome? Perspect Psychiatr Care (2010) 0.85
Possible neuroleptic malignant syndrome associated with paliperidone. J Neuropsychiatry Clin Neurosci (2007) 0.85
Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy (2005) 0.85
Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol (2007) 0.84
Clinical risk factors for neuroleptic malignant syndrome. Hum Psychopharmacol (2002) 0.84
Risperidone-induced bulbar palsy-like syndrome. Dysphagia (2010) 0.84
Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol (2005) 0.83
An atypical case of neuroleptic malignant syndrome precipitated by valproate. BMJ Case Rep (2014) 0.83
Paliperidone-associated atypical neuroleptic malignant syndrome: a case report. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.83
Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. Aging Clin Exp Res (2006) 0.83
A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation. Gen Hosp Psychiatry (2011) 0.82
Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit (2011) 0.82
Paliperidone-induced neuroleptic malignant syndrome. J Neuropsychiatry Clin Neurosci (2011) 0.82
Neuroleptic malignant syndrome associated with olanzapine. Aust N Z J Psychiatry (1998) 0.82
Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatry (2007) 0.81
Risk of neuroleptic malignant syndrome in patients with bipolar disorder: a retrospective, population-based case-control study. Int J Psychiatry Med (2009) 0.81
Olanzapine for nausea and vomiting. Am J Hosp Palliat Care (2010) 0.80
Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate. J Clin Psychiatry (2004) 0.80
Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions. Biol Pharm Bull (2013) 0.80
Neuroleptic malignant syndrome. The results of a 6-month prospective study of incidence in a state psychiatric hospital. Clin Neuropharmacol (1988) 0.79
Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology (1996) 0.79
Neuroleptic Malignant Syndrome with ziprasidone. J Clin Psychopharmacol (2002) 0.79
Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: a case report. J Clin Psychopharmacol (2009) 0.78
Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge. Hum Psychopharmacol (2004) 0.78
Ascertaining instances of neuroleptic malignant syndrome in a secondary mental healthcare electronic medical records database: the SLAM BRC Case Register. Ther Adv Psychopharmacol (2012) 0.77
Malignant catatonia in a patient with bipolar disorder, B12 deficiency, and neuroleptic malignant syndrome: one cause or three? J Psychiatr Pract (2009) 0.77
Neuroleptic malignant syndrome following cardiac surgery: successful treatment with dantrolene. Eur J Cardiothorac Surg (2003) 0.76
Neuroleptic malignant syndrome under treatment with antidepressants? A critical review. Eur Arch Psychiatry Clin Neurosci (1998) 0.76
Neuroleptic malignant syndrome with olanzapine associated with severe hypernatremia. Hum Psychopharmacol (2001) 0.76
Zotepine: a clinical review. Expert Opin Drug Metab Toxicol (2009) 0.76
Chronic olanzapine, serotonin receptors, and subsequent serotonin toxicity. J Clin Psychopharmacol (2010) 0.76
Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine. Indian J Med Sci (2007) 0.76
Neuroleptic malignant syndrome in elderly patients. Expert Rev Neurother (2007) 0.76
A self-limiting case of atypical neuroleptic malignant syndrome associated with zotepine. J Clin Psychopharmacol (2011) 0.76
Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Neuropsychiatr Dis Treat (2006) 0.76
Neuroleptic malignant syndrome with dermatologic complications. J Clin Psychopharmacol (2004) 0.76
Amisulpride and neuroleptic malignant syndrome. Chang Gung Med J (2011) 0.76
Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry (2011) 0.76
Possible contribution of XYY syndrome to neuroleptic malignant syndrome in a child receiving quetiapine. Am J Health Syst Pharm (2010) 0.76
Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. Clin Neuropharmacol (2007) 0.75
Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. Can J Psychiatry (2012) 0.75
Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord (2006) 2.74
Mental illness in homicide-suicide: a review. J Am Acad Psychiatry Law (2012) 2.16
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol (2009) 2.14
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol (2013) 1.62
Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain (2009) 1.60
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) (2011) 1.45
Suicide in bipolar disorder: Risks and management. CNS Spectr (2006) 1.43
Integration of suicidology with general medicine: an obligation to society. Patient Educ Couns (2011) 1.42
BDNF plasma levels variations in major depressed patients receiving duloxetine. Neurol Sci (2014) 1.41
Shibari: double hanging during consensual sexual asphyxia. Arch Sex Behav (2012) 1.39
Insomnia cycling with a 42-day infradian period: evidence for two uncoupled circadian oscillators? Sleep Med (2010) 1.38
Psychiatric comorbidity and suicide risk in patients with chronic migraine. Neuropsychiatr Dis Treat (2010) 1.37
Psychometric properties of the stagnation scale in medication overuse headache patients. J Headache Pain (2015) 1.29
Suicide among Italian adolescents: 1970-2002. Eur Child Adolesc Psychiatry (2009) 1.26
Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy. J Affect Disord (2006) 1.24
Suicidal risk in antidepressant drug trials. Arch Gen Psychiatry (2006) 1.24
Indications for electroconvulsive treatment in schizophrenia: a systematic review. Schizophr Res (2013) 1.22
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry (2002) 1.19
Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord (2013) 1.19
Suicidal behavior and alcohol abuse. Int J Environ Res Public Health (2010) 1.15
Do stroke patients have an increased risk of developing suicidal ideation or dying by suicide? An overview of the current literature. CNS Neurosci Ther (2012) 1.13
Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all. J Hepatol (2009) 1.12
"Wait and see" policy for early hepatocellular carcinoma. J Hepatol (2013) 1.09
The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention. Eur Arch Psychiatry Clin Neurosci (2010) 1.07
Sequential or combined treatment? That is the question. Radiology (2014) 1.07
Life events as precipitants of suicide attempts among first-time suicide attempters, repeaters, and non-attempters. Psychiatry Res (2011) 1.07
Completed suicide in schizophrenia: evidence from a case-control study. Psychiatry Res (2009) 1.04
Posttraumatic stress disorder and suicide risk among veterans: a literature review. J Nerv Ment Dis (2013) 1.02
Suicide risk in first episode psychosis: a selective review of the current literature. Schizophr Res (2011) 1.01
Anatomical and functional correlates in major depressive disorder: the contribution of neuroimaging studies. World J Biol Psychiatry (2010) 1.00
Suicidal behavior in bipolar disorder: epidemiology, characteristics and major risk factors. J Affect Disord (2012) 1.00
Periventricular white matter hyperintensities as predictors of suicide attempts in bipolar disorders and unipolar depression. Prog Neuropsychopharmacol Biol Psychiatry (2008) 1.00
Does the level of education influence completed suicide? A nationwide register study. J Affect Disord (2012) 1.00
Bereavement after the suicide of a significant other. Indian J Psychiatry (2013) 0.99
Promising medications for cocaine dependence treatment. Recent Pat CNS Drug Discov (2011) 0.98
Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res (2012) 0.98
Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol (2009) 0.97
Facial reactions in response to dynamic emotional stimuli in different modalities in patients suffering from schizophrenia: a behavioral and EMG study. Front Hum Neurosci (2013) 0.97
Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk. Expert Rev Neurother (2009) 0.96
Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. World J Biol Psychiatry (2013) 0.96
Suicide and marital status in Italy. Psychiatr Q (2008) 0.96
The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry (2014) 0.96
Suicide mortality in Italy from 1980 to 2002. Psychiatry Res (2009) 0.96
Substance abuse and suicide risk among adolescents. Eur Arch Psychiatry Clin Neurosci (2012) 0.95
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol (2009) 0.95
Vitamin D and psychosis: mini meta-analysis. Schizophr Res (2013) 0.95
White matter hyperintensities and their associations with suicidality in patients with major affective disorders. Eur Arch Psychiatry Clin Neurosci (2007) 0.95
The involvement of microRNAs in major depression, suicidal behavior, and related disorders: a focus on miR-185 and miR-491-3p. Cell Mol Neurobiol (2013) 0.95
Hepatocellular carcinomas <2 cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. Liver Int (2004) 0.94
Mood disorders medications: predictors of nonadherence - review of the current literature. Expert Rev Neurother (2013) 0.94
Overattachment and perceived disability in chronic migraineurs. Clin Neurol Neurosurg (2012) 0.94
Use of Liver Imaging and Biopsy in Clinical Practice. N Engl J Med (2017) 0.94
Affective temperamental profiles are associated with white matter hyperintensity and suicidal risk in patients with mood disorders. J Affect Disord (2010) 0.93
Assessment and treatment of suicide risk in bipolar disorders. Expert Rev Neurother (2009) 0.93
Suicide in the elderly: a psychological autopsy study in a North Italy area (1994-2004). Am J Geriatr Psychiatry (2008) 0.91
Psychometric properties of the Gotland Scale for Depression in Italian psychiatric inpatients and its utility in the prediction of suicide risk. J Affect Disord (2011) 0.91
Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology (2004) 0.91
Nearly lethal resuscitated suicide attempters have no low serum levels of cholesterol and triglycerides. Psychol Rep (2010) 0.91
Liver transplantation for Wilson's disease: The burden of neurological and psychiatric disorders. Liver Transpl (2005) 0.90
Quality of life and suicide risk in patients with diabetes mellitus. Psychosomatics (2009) 0.90
Psychobiological responses to unpleasant emotions in cannabis users. Eur Arch Psychiatry Clin Neurosci (2011) 0.90
Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord (2011) 0.89
The role of microRNAs in synaptic plasticity, major affective disorders and suicidal behavior. Neurosci Res (2012) 0.89
Mental turmoil, suicide risk, illness perception, and temperament, and their impact on quality of life in chronic daily headache. J Headache Pain (2008) 0.89
Suicide risk in depression and bipolar disorder: Do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent? Neuropsychiatr Dis Treat (2008) 0.89
[Suicide prevention and the role of the psychiatrist]. Riv Psichiatr (2014) 0.89